North America Gastric Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 843.49 |
 CAGR |
% |
| Major Markets Players |
北美胃癌诊断市场，按产品类型（仪器、试剂和消耗品、服务）、诊断类型（确认测试、胃癌筛查测试/体检）、年龄组（成人、儿童和老年病学）、疾病类型（肠腺癌或弥漫性腺癌、类癌瘤、胃肠道间质瘤(GIST)、胃淋巴瘤等）、分期（0 期、I 期、II 期、III 期）、性别（男性和女性）、样本类型（血液、组织、尿液和粪便）、最终用户（诊断实验室、医院、癌症研究机构、肿瘤专科诊所等）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测到 2030 年。
北美胃癌诊断市场分析与洞察
北美老年人口的增长推动了胃癌诊断行业的增长。胃肠道肿瘤和淋巴瘤的流行也刺激了对胃癌诊断的需求。关键的市场制约因素是需要降低与癌症诊断测试相关的高价格，以便发展中国家也能从中受益。
大量市场参与者正在提供具有创新的胃癌诊断产品，为北美胃癌诊断市场的增长铺平了道路。
Data Bridge Market Research 分析，北美胃癌诊断市场预计到 2030 年将达到 8.4349 亿美元的价值，预测期内的复合年增长率为 8.5%。由于对试剂盒和试剂的需求不断增加，试剂和耗材占据了市场中最大的产品类型细分市场，而医疗支出的增加加速了对智能医疗设备的需求。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按产品类型（仪器、试剂和耗材、服务）、诊断类型（确认测试、胃癌筛查测试/体检）、年龄组（成人、儿童和老年病学）、疾病类型（肠或弥漫性腺癌、类癌瘤、胃肠道间质瘤 (GIST)、胃淋巴瘤等）、分期（0 期、I 期、II 期、III 期）、性别（男性和女性）、样本类型（血液、组织、尿液和粪便）、最终用户（诊断实验室、医院、癌症研究机构、肿瘤专科诊所等）、分销渠道（直接招标和零售） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES Pte Ltd., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc., QIAGEN, and among others |
Market Definition
Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.
Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.
North America Gastric Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma
According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.
It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.
Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the North America gastric cancer diagnostics market.
- Rise in alcohol consumption and surge in smoking
Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.
A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.
Thus, the rise in alcohol consumption and surge in smoking is expected to drive the North America gastric cancer market growth.
Opportunity
-
Rise in adoption of automated systems
Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.
Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.
Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.
Restraint/Challenge
- Lack of sufficient financial support from health insurance policies
To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.
Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).
Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.
Recent Developments
- In October 2022, General Electric Company collaborated with several research institutes such as the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics
- In March 2020, Thermo Fisher Scientific Inc. announced that it would be acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company will increase its product portfolio in the market, leading to increased revenue in future
North America Gastric Cancer Diagnostics Market Scope
The North America gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, type, stage, gender, sample, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
PRODUCT TYPE
- Instruments
- Reagents & Consumables
- Services
On the basis of product type, the market is segmented into instruments, reagents & consumables, and services.
DIAGNOSTIC TYPE
- Confirmatory Test
- Gastric Cancer Screening Tests/Physical Exam
On the basis of diagnostics type, the market is segmented into gastric cancer screening tests/physical exam and confirmatory tests.
AGE GROUP
- Adult
- Pediatric
- Geriatrics
On the basis of age group, the market is segmented into adult, pediatric, and geriatrics.
TYPE
- Intestinal Or Diffuse Adenocarcinoma
- Carcinoid Tumor
- Gastrointestinal Stromal Tumor (GIST)
- Gastric Lymphoma
- Others
On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.
STAGE
- Stage 0
- Stage I
- Stage II
- Stage III
On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.
GENDER
- Male
- Female
On the basis of gender, the market is segmented into male and female.
SAMPLE TYPE
- Blood
- Tissue
- Urine
- Stool
On the basis of sample type, the market is segmented into blood, tissue, urine, and stool.
END USER
- Diagnostic Laboratories
- Hospitals
- Cancer Research Institutes
- Oncology Specialty Clinics
- Others
On the basis of end users, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.
DISTRIBUTION CHANNEL
- Direct Tenders
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
North America Gastric Cancer Diagnostics Market Regional Analysis/Insights
北美胃癌诊断市场根据产品类型、诊断类型、年龄组、疾病类型、阶段、性别、样本、最终用户和分销渠道分为九个显著的部分。
该市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于医疗保健行业技术进步的不断加快，美国预计将占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。
竞争格局和胃癌诊断市场份额分析
北美胃癌诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对北美胃癌诊断市场的关注有关。
北美胃癌诊断市场的一些主要参与者包括 BIOMÉRIEUX、Myriad Genetics, Inc.、ACON Laboratories, Inc.、Teco Diagnostics、Vela Diagnostics、Abbott、AdvaCare Pharma、MiRXES Pte Ltd.、Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd、General Electric、Agilent Technologies, Inc.、Biohit Oyj、BIOCEPT, INC.、FOUNDATION MEDICINE, INC.、DiaSorin SpA、Paragon Genomics, Inc.、QIAGEN 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.4 BRAND ANALYSIS
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET
4.6 INDUSTRY INSIGHTS:
5 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY
5.1 NORTH AMERICA
5.1.1 REGULATORY SCENARIO IN THE U.S
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
6.1.3 INCREASE IN THE GERIATRIC POPULATION
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES
6.3 OPPORTUNITIES
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES
6.4.2 LIMITATIONS OF RADIATION TESTS
7 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.2.1 KITS
7.2.1.1 DNA POLYMERASE KITS
7.2.1.2 PCR KITS
7.2.1.3 NUCLEIC ACID ISOLATION KITS
7.2.1.4 OTHERS
7.2.2 REAGENTS
7.2.2.1 ASSAYS
7.2.2.2 BUFFERS
7.2.2.3 PRIMERS
7.2.2.4 OTHERS
7.3 INSTRUMENTS
7.4 SERVICES
8 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
8.1 OVERVIEW
8.2 CONFIRMATORY TEST
8.2.1 IMAGING TESTS
8.2.1.1 PET SCAN/CT SCAN
8.2.1.2 CT SCAN
8.2.1.3 ULTRASOUND
8.2.1.4 MRI
8.2.1.5 X-RAY
8.2.2 BIOMARKER
8.2.2.1 DNA BIOMARKER
8.2.2.2 RNA BIOMARKER
8.2.2.3 PROTEIN BIOMARKER
8.2.3 BIOPSY
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM
9 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 GERIATRICS
9.3 ADULT
9.4 PEDIATRIC
10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA
10.3 CARCINOID TUMOR
10.4 GASTROINTESTINAL STROMAL TUMOR
10.5 GASTRIC LYMPHOMA
10.6 OTHERS
11 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE
11.1 OVERVIEW
11.2 STAGE I
11.2.1 STAGE IA
11.2.2 STAGE IB
11.3 STAGE II
11.3.1 STAGE IIA
11.3.2 STAGE IIB
11.4 STAGE III
11.4.1 STAGE IIIA
11.4.2 STAGE IIIB
11.4.3 STAGE IIIC
11.5 STAGE 0
12 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
13.1 OVERVIEW
13.2 STOOL
13.3 TISSUE
13.4 BLOOD
13.5 URINE
14 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC LABORATORIES
14.4 CANCER RESEARCH INSTITUTES
14.5 ONCOLOGY SPECIALTY CLINICS
14.6 OTHERS
15 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 GENERAL ELECTRIC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 ABBOTT
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 QIAGEN
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 MYRIAD GENETICS, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACON LABORATORIES, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ADVACARE PHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 AGILENT TECHNOLOGIES, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BIOMÉRIEUX
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BIOCEPT, INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 BIOHIT OYJ
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 DIASORIN S.P.A
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 ENDOFOTONICS PTE LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 FOUNDATION MEDICINE, INC.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 FUJIREBIO (AN H.U. GROUP COMPANY)
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 MIRXES PTE LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 PARAGON GENOMICS, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 TECO DIAGNOSTICS
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 VELA DIAGNOSTICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE
TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-
TABLE 3 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 70 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.S. REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 75 U.S. CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 79 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 80 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 81 U.S. STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 82 U.S. STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 83 U.S. STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 84 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 85 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 86 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 87 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 88 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 CANADA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 CANADA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 93 CANADA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 94 CANADA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 95 CANADA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 96 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 97 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 99 CANADA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 100 CANADA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 101 CANADA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 102 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 103 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 104 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 105 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 106 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 MEXICO REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 MEXICO KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 MEXICO REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 110 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 111 MEXICO CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 112 MEXICO IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 113 MEXICO BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 114 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 115 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 119 MEXICO STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 121 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 122 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 123 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID
FIGURE 11 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET
FIGURE 15 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 17 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 18 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022
FIGURE 20 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)
FIGURE 21 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)
FIGURE 22 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 24 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 25 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 26 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 27 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022
FIGURE 28 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)
FIGURE 29 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)
FIGURE 30 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022
FIGURE 32 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)
FIGURE 33 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)
FIGURE 34 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE
FIGURE 35 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 36 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 37 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022
FIGURE 40 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 41 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 42 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 43 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 44 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 52 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 53 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 56 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
